PRIMAL STUDY: A Phase 1b, Open-label, Multicenter, Multinational Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel (PDoc) in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 10 May 2017
At a glance
- Drugs Hyaluronidase (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms PRIMAL
- Sponsors Halozyme Therapeutics
- 04 May 2017 Status changed from active, no longer recruiting to discontinued.
- 12 Oct 2016 Planned End Date changed from 1 Feb 2018 to 1 Mar 2017.
- 12 Oct 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2016.